Klivira
Request demo

Navigating Fasenra Prior Authorization for Orthopedics

Efficiently managing **Fasenra prior authorization for orthopedics** requires a nuanced understanding of biologic PA requirements within a high-volume surgical practice.

Orthopedic practices frequently manage patients with complex co-morbidities, including inflammatory conditions that may necessitate biologic therapies like Fasenra. While Fasenra is not typically prescribed by orthopedic surgeons, coordinating its prior authorization for patients under orthopedic care can introduce significant administrative overhead and impact patient treatment timelines. Klivira provides a structured approach to automate and streamline these complex PA workflows.

Fasenra's Role in Orthopedic Patient Care

Fasenra (benralizumab) is a targeted biologic therapy primarily indicated for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). While orthopedists do not typically prescribe Fasenra, patients with EGPA may present with musculoskeletal manifestations such as arthralgia or myalgia, bringing them into orthopedic care. In such scenarios, orthopedic practices may need to coordinate or be aware of the prior authorization requirements for Fasenra to ensure comprehensive patient management alongside their primary prescribing specialists.

Key Documentation for Fasenra Prior Authorization

  • Confirmed diagnosis (e.g., ICD-10 for severe eosinophilic asthma or EGPA).
  • Documented peripheral blood eosinophil count (typically above a specified threshold).
  • History of failed trials of conventional or alternative therapies (e.g., high-dose inhaled corticosteroids for asthma).
  • Relevant pulmonary function test (PFT) results, if applicable.
  • Detailed symptom severity and frequency logs.
  • Absence of specific contraindications as per prescribing information.

Common Prior Authorization Challenges for Biologics in Orthopedic Settings

Managing prior authorizations for biologics like Fasenra within an orthopedic practice presents unique challenges. These include navigating complex step therapy protocols, meeting stringent medical necessity criteria, completing payer-specific forms, and coordinating comprehensive clinical documentation across multiple specialties. These tasks can divert orthopedic staff from their primary focus on surgical and imaging PAs, leading to administrative bottlenecks and potential treatment delays for patients.

Typical Denial Reasons for Fasenra and Similar Biologics

  • Insufficient trial or failure to meet step therapy requirements for preferred alternatives.
  • Lack of documented diagnostic criteria, such as an eosinophil count below the payer's threshold.
  • Incomplete or inconsistent clinical documentation, including missing PFTs or symptom scores.
  • Request for off-label use without specific payer coverage policies.
  • Failure to meet re-authorization criteria or demonstrate continued clinical benefit.

Streamlining Biologic PAs with Klivira in Orthopedic Practices

Klivira's platform automates the prior authorization process by integrating seamlessly with EMRs via SMART on FHIR, extracting essential clinical data like eosinophil counts, diagnostic codes, and treatment history. This automation reduces the manual burden on orthopedic staff by intelligently routing requests to the appropriate payer channels, including X12 278 transactions or specific payer portals, and managing the complex documentation required for biologic approvals.

Klivira's Comprehensive Approach to Orthopedic Prior Authorization

Beyond specific biologic PAs, Klivira offers a holistic solution for orthopedic practices. Our platform incorporates AAOS-guideline-aware conservative-care logic, intelligently routes advanced imaging requests to specialty benefit-management vendors, and orchestrates multi-step PA cascades common in orthopedics (e.g., imaging → surgery → DME). We also automate the collection of BMI and imaging documentation from EMR FHIR queries and integrate peer-to-peer scheduling for clinical-necessity denials, ensuring efficiency across all orthopedic PA needs.

Frequently asked questions

Is Fasenra commonly prescribed by orthopedic surgeons?

No, Fasenra (benralizumab) is a biologic typically prescribed by pulmonologists, allergists, or rheumatologists for conditions like severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Orthopedic surgeons primarily focus on musculoskeletal conditions and procedures.

Why would an orthopedic practice need to understand Fasenra prior authorization?

Orthopedic practices often treat patients with complex co-morbidities. If a patient under orthopedic care requires Fasenra, the practice's revenue cycle or prior authorization team may need to coordinate documentation or understand the PA process to ensure holistic patient management and avoid delays in overall care.

What are the primary indications for Fasenra that trigger prior authorization?

The primary indications for Fasenra that typically require prior authorization include severe eosinophilic asthma in adults and adolescents aged 12 years and older, and eosinophilic granulomatosis with polyangiitis (EGPA) in adults.

How does Klivira assist with prior authorization for biologics like Fasenra?

Klivira automates the prior authorization process by integrating with EMRs to extract necessary clinical data (e.g., eosinophil counts, diagnostic codes, treatment history). It then intelligently routes requests to the appropriate payer channels (e.g., X12 278, payer portals) and helps manage the complex documentation required for biologic approvals, reducing manual burden.

What are common reasons for Fasenra prior authorization denials?

Common denial reasons for Fasenra include insufficient documentation of eosinophil counts, failure to meet step therapy requirements (e.g., trial of other asthma medications), incomplete clinical history, or lack of documented severe disease criteria as defined by payer policies.

Related coverage

Other fasenra prior authorization by payer

Other fasenra prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo